ITCI Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 3.40%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $40,434,286.15

Intra-Cellular Therapies Insider Trading History Chart

Intra-Cellular Therapies Share Price & Price History

^$80.39

▼ -0.45 (-0.56%)

As of 07/26/2024 01:00 AM ET

Days: 30 | 90 | 365

“Generational Bull Run” Incoming

From Unstoppable Prosperity | Ad

LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.

You can find out what they are by clicking here now.

Intra-Cellular Therapies Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/24/2024	Rory B. Riggs	Director	Sell	4,462	$75.57	$337,193.34	116,600
6/18/2024	Robert L. Van Nostrand	Director	Sell	20,000	$75.91	$1,518,200.00	9,690
3/11/2024	Lawrence J. Hineline	CFO	Sell	10,121	$65.96	$667,581.16
3/11/2024	Michael Halstead	EVP	Sell	7,345	$65.97	$484,549.65	19,803
3/11/2024	Sharon Mates	CEO	Sell	20,565	$65.21	$1,341,043.65	1,050,309
3/7/2024	Lawrence J. Hineline	CFO	Sell	13,132	$66.60	$874,591.20	29,700
3/7/2024	Sharon Mates	CEO	Sell	40,712	$66.50	$2,707,348.00	1,050,309
3/7/2024	Suresh K. Durgam	EVP	Sell	6,450	$66.56	$429,312.00	16,170
2/26/2024	Joel S. Marcus	Director	Sell	26,328	$68.68	$1,808,207.04	39,662
2/26/2024	Lawrence J. Hineline	CFO	Sell	13,337	$69.43	$925,987.91
2/26/2024	Michael Halstead	EVP	Sell	7,907	$69.53	$549,773.71	29,700
2/26/2024	Sharon Mates	CEO	Sell	22,590	$69.79	$1,576,556.10	1,050,309
1/18/2024	Sharon Mates	CEO	Sell	67,917	$65.19	$4,427,509.23	1,050,309
1/16/2024	Sharon Mates	CEO	Sell	75,361	$67.25	$5,068,027.25	1,050,309
1/11/2024	Michael Halstead	EVP	Sell	50,000	$66.83	$3,341,500.00
1/2/2024	Suresh K. Durgam	EVP	Sell	62,282	$70.60	$4,397,109.20
12/13/2023	Suresh K. Durgam	EVP	Sell	21,262	$65.00	$1,382,030.00
11/6/2023	Mark Neumann	EVP	Sell	42,393	$55.63	$2,358,322.59	29,700
9/18/2023	Sharon Mates	CEO	Sell	55,587	$53.76	$2,988,357.12	1,094,722
8/7/2023	Mark Neumann	EVP	Sell	55,300	$58.79	$3,251,087.00	45,339
7/17/2023	Suresh K. Durgam	EVP	Sell	1,842	$65.00	$119,730.00	21,262
6/14/2023	Lawrence J. Hineline	CFO	Sell	81,854	$63.97	$5,236,200.38
4/17/2023	Robert L. Van Nostrand	Director	Sell	10,000	$63.00	$630,000.00	9,345
3/28/2023	Mark Neumann	EVP	Sell	15,604	$54.31	$847,453.24	45,339
3/13/2023	Lawrence J. Hineline	CFO	Sell	5,582	$44.93	$250,799.26
3/13/2023	Sharon Mates	CEO	Sell	20,565	$44.99	$925,219.35	1,130,309
3/13/2023	Suresh K. Durgam	EVP	Sell	7,344	$45.04	$330,773.76	23,104
3/10/2023	Lawrence J. Hineline	CFO	Sell	15,663	$43.06	$674,448.78
3/10/2023	Mark Neumann	EVP	Sell	8,550	$43.34	$370,557.00	57,357
3/10/2023	Sharon Mates	CEO	Sell	41,770	$43.15	$1,802,375.50	1,130,309
3/1/2023	Mark Neumann	EVP	Sell	7,241	$50.01	$362,122.41	49,199
2/24/2023	Lawrence J. Hineline	CFO	Sell	7,455	$47.03	$350,608.65
2/24/2023	Mark Neumann	EVP	Sell	4,046	$47.12	$190,647.52	56,440
2/24/2023	Sharon Mates	CEO	Sell	22,590	$47.03	$1,062,407.70	1,100,309
2/24/2023	Suresh K. Durgam	SVP	Sell	7,906	$47.14	$372,688.84	23,104
2/21/2023	Lawrence J. Hineline	CFO	Sell	10,443	$46.82	$488,941.26
2/21/2023	Mark Neumann	EVP	Sell	3,898	$47.01	$183,244.98	52,580
2/21/2023	Sharon Mates	CEO	Sell	27,848	$46.83	$1,304,121.84	1,100,309
2/21/2023	Suresh K. Durgam	SVP	Sell	8,354	$46.84	$391,301.36	23,104
2/17/2023	Lawrence J. Hineline	CFO	Sell	53,968	$49.83	$2,689,225.44
12/19/2022	Joel S. Marcus	Director	Sell	5,000	$50.82	$254,100.00	29,233
12/13/2022	Sharon Mates	CEO	Sell	33,083	$55.00	$1,819,565.00	1,100,309
12/1/2022	Michael Halstead	EVP	Sell	50,000	$53.73	$2,686,500.00
9/21/2022	Lawrence J. Hineline	CFO	Sell	65,164	$45.63	$2,973,433.32
8/11/2022	Robert L. Van Nostrand	Director	Sell	30,000	$57.13	$1,713,900.00	9,043
5/12/2022	Joel S. Marcus	Director	Sell	10,000	$55.00	$550,000.00	54,233
4/8/2022	Mark Neumann	EVP	Sell	86,348	$64.37	$5,558,220.76	45,339
3/18/2022	Rory B. Riggs	Director	Sell	20,637	$61.18	$1,262,571.66
3/16/2022	Rory B. Riggs	Director	Sell	64,534	$59.27	$3,824,930.18
3/7/2022	Joel S. Marcus	Director	Sell	5,000	$54.52	$272,600.00
3/4/2022	Suresh K. Durgam	Insider	Sell	3,860	$55.52	$214,307.20
3/2/2022	Suresh K. Durgam	Insider	Sell	4,177	$56.98	$238,005.46
2/24/2022	Lawrence J. Hineline	CFO	Sell	7,454	$51.97	$387,384.38
2/24/2022	Mark Neumann	EVP	Sell	7,906	$52.21	$412,772.26
2/24/2022	Sharon Mates	CEO	Sell	22,589	$51.98	$1,174,176.22
2/24/2022	Suresh K. Durgam	Insider	Sell	4,046	$52.27	$211,484.42
2/22/2022	Lawrence J. Hineline	CFO	Sell	10,443	$55.40	$578,542.20
2/22/2022	Mark Neumann	EVP	Sell	11,139	$55.29	$615,875.31
2/22/2022	Sharon Mates	CEO	Sell	27,847	$55.39	$1,542,445.33
2/22/2022	Suresh K. Durgam	Insider	Sell	4,177	$55.29	$230,946.33
1/18/2022	Suresh K. Durgam	Insider	Sell	6,223	$42.03	$261,552.69
1/10/2022	Lawrence J. Hineline	CFO	Sell	19,639	$40.76	$800,485.64
1/10/2022	Mark Neumann	EVP	Sell	20,948	$40.78	$854,259.44
1/10/2022	Sharon Mates	CEO	Sell	41,896	$40.78	$1,708,518.88
1/10/2022	Suresh K. Durgam	Insider	Sell	6,870	$40.76	$280,021.20
12/21/2021	Lawrence J. Hineline	CFO	Sell	175,000	$47.59	$8,328,250.00
12/21/2021	Michael Halstead	EVP	Sell	176,863	$47.56	$8,411,604.28
10/18/2021	Mark Neumann	EVP	Sell	13,448	$40.86	$549,485.28
10/18/2021	Sharon Mates	CEO	Sell	8,192	$40.00	$327,680.00
10/15/2021	Sharon Mates	CEO	Sell	40,392	$40.00	$1,615,680.00

Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”

From Paradigm Press | Ad

Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.

Click here to see it because it’s a SHOCKER…

SEC Filings (Institutional Ownership Changes) for Intra-Cellular Therapies (NASDAQ:ITCI)

92.33% of Intra-Cellular Therapies stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Intra-Cellular Therapies Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
7/26/2024	Legato Capital Management LLC	24,582	$1.68M	0.2%	+67.7%	0.023%
7/26/2024	Summit Securities Group LLC	816	$56K	0.0%	N/A	0.001%
7/26/2024	Allspring Global Investments Holdings LLC	69,696	$4.77M	0.0%	+325.7%	0.066%
7/26/2024	Bank of New York Mellon Corp	349,148	$23.91M	0.0%	-7.2%	0.331%
7/26/2024	EFG Asset Management North America Corp.	34,452	$2.36M	0.4%	+0.5%	0.033%
7/25/2024	Raymond James Trust N.A.	3,215	$0.22M	0.0%	-5.7%	0.003%
7/25/2024	Calamos Advisors LLC	16,404	$1.12M	0.0%	+86.1%	0.016%
7/22/2024	Pallas Capital Advisors LLC	4,120	$0.31M	0.0%	N/A	0.004%
7/20/2024	China Universal Asset Management Co. Ltd.	12,403	$0.85M	0.1%	-33.4%	0.012%
7/20/2024	Nisa Investment Advisors LLC	4,168	$0.29M	0.0%	-3.2%	0.004%
7/20/2024	Hennion & Walsh Asset Management Inc.	16,511	$1.13M	0.1%	-0.8%	0.016%
7/19/2024	Raymond James & Associates	154,527	$10.58M	0.0%	-1.0%	0.146%
7/19/2024	Franklin Street Advisors Inc. NC	10,783	$0.74M	0.1%	-21.8%	0.010%
7/18/2024	Assenagon Asset Management S.A.	342,843	$23.48M	0.1%	-47.2%	0.325%
7/17/2024	Quantum Private Wealth LLC	38,261	$2.62M	0.9%	+2.9%	0.036%
7/17/2024	AlphaMark Advisors LLC	4,219	$0.29M	0.1%	N/A	0.004%
7/17/2024	Oak Ridge Investments LLC	11,839	$0.81M	0.1%	N/A	0.011%
7/16/2024	Envestnet Portfolio Solutions Inc.	4,117	$0.28M	0.0%	-8.9%	0.004%
7/12/2024	SG Americas Securities LLC	48,778	$3.34M	0.0%	+962.7%	0.046%
7/11/2024	OLD National Bancorp IN	6,300	$0.43M	0.0%	-69.7%	0.006%
7/10/2024	CWM LLC	1,372	$94K	0.0%	+83.9%	0.001%
7/9/2024	Harbor Capital Advisors Inc.	14,298	$0.98M	0.1%	N/A	0.014%
7/5/2024	DNB Asset Management AS	80,155	$5.48M	0.0%	+20.1%	0.076%
7/2/2024	First Hawaiian Bank	6,466	$0.44M	0.0%	+8.3%	0.006%
5/28/2024	Teachers Retirement System of The State of Kentucky	10,298	$0.71M	0.0%	-6.0%	0.010%
5/24/2024	Farallon Capital Management LLC	231,000	$15.99M	0.1%	N/A	0.219%
5/17/2024	Castleark Management LLC	54,230	$3.75M	0.2%	-26.5%	0.051%
5/17/2024	Tidal Investments LLC	3,698	$0.26M	0.0%	+13.9%	0.004%
5/16/2024	California State Teachers Retirement System	87,844	$6.08M	0.0%	-5.0%	0.083%
5/16/2024	Janus Henderson Group PLC	401,357	$27.77M	0.0%	-17.9%	0.380%
5/16/2024	Kennedy Capital Management LLC	19,321	$1.34M	0.0%	-29.4%	0.018%
5/16/2024	Silvercrest Asset Management Group LLC	42,276	$2.93M	0.0%	-24.2%	0.040%
5/15/2024	Public Employees Retirement System of Ohio	55,830	$3.86M	0.0%	-0.5%	0.053%
5/15/2024	Bellevue Group AG	2,819,482	$195.11M	3.0%	-8.1%	2.671%
5/15/2024	Price T Rowe Associates Inc. MD	1,203,968	$83.32M	0.0%	-4.5%	1.140%
5/15/2024	Avoro Capital Advisors LLC	2,475,000	$171.27M	2.0%	+9.7%	2.344%
5/15/2024	Affinity Asset Advisors LLC	50,000	$3.46M	0.4%	N/A	0.047%
5/14/2024	EntryPoint Capital LLC	2,167	$0.15M	0.1%	+138.7%	0.002%
5/14/2024	Natixis	3,733	$0.26M	0.0%	+165.9%	0.004%
5/14/2024	CANADA LIFE ASSURANCE Co	17,023	$1.18M	0.0%	+106.0%	0.016%
5/14/2024	American International Group Inc.	46,180	$3.20M	0.0%	-0.9%	0.044%
5/13/2024	Clearbridge Investments LLC	1,744,551	$120.72M	0.1%	+12.3%	1.653%
5/11/2024	Covestor Ltd	2,644	$0.18M	0.1%	-6.5%	0.003%
5/11/2024	Cynosure Group LLC	4,594	$0.32M	0.1%	N/A	0.005%
5/11/2024	Edgestream Partners L.P.	18,137	$1.26M	0.1%	+35.0%	0.019%
5/10/2024	Vanguard Group Inc.	9,225,981	$638.44M	0.0%	+1.4%	9.530%
5/9/2024	Orion Portfolio Solutions LLC	24,612	$1.70M	0.0%	-2.0%	0.025%
5/9/2024	Lord Abbett & CO. LLC	472,687	$32.71M	0.1%	-38.8%	0.488%
5/9/2024	SageView Advisory Group LLC	15,196	$1.05M	0.1%	N/A	0.016%
5/9/2024	State Board of Administration of Florida Retirement System	28,496	$1.97M	0.0%	+6.3%	0.029%
5/8/2024	BNP PARIBAS ASSET MANAGEMENT Holding S.A.	265,597	$18.38M	0.0%	N/A	0.274%
5/8/2024	ProShare Advisors LLC	23,621	$1.64M	0.0%	+9.1%	0.024%
5/8/2024	Russell Investments Group Ltd.	50,845	$3.52M	0.0%	+232.0%	0.053%
5/8/2024	Headlands Technologies LLC	468	$32K	0.0%	N/A	0.000%
5/8/2024	Inspire Investing LLC	5,154	$0.36M	0.0%	-4.0%	0.005%
5/7/2024	Sei Investments Co.	128,311	$8.88M	0.0%	+9.8%	0.133%
5/7/2024	Quantum Private Wealth LLC	37,199	$2.57M	1.0%	+56.9%	0.038%
5/7/2024	Swiss National Bank	170,900	$11.83M	0.0%	+0.3%	0.177%
5/7/2024	ClariVest Asset Management LLC	4,970	$0.34M	0.0%	N/A	0.005%
5/7/2024	TimesSquare Capital Management LLC	383,211	$26.52M	0.4%	-22.8%	0.396%
5/7/2024	Lisanti Capital Growth LLC	53,285	$3.69M	0.9%	+0.8%	0.055%
5/7/2024	Oppenheimer Asset Management Inc.	29,110	$2.01M	0.0%	-16.3%	0.030%
5/7/2024	SG Americas Securities LLC	4,590	$0.32M	0.0%	+50.8%	0.005%
5/6/2024	Envestnet Portfolio Solutions Inc.	4,518	$0.31M	0.0%	-5.1%	0.005%
5/3/2024	Essex Investment Management Co. LLC	1,233	$85K	0.0%	-28.7%	0.001%
5/3/2024	Central Pacific Bank Trust Division	3,350	$0.23M	0.0%	N/A	0.003%
5/2/2024	Jennison Associates LLC	9,212	$0.64M	0.0%	N/A	0.010%
5/2/2024	Mutual of America Capital Management LLC	46,431	$3.21M	0.0%	-7.5%	0.048%
5/2/2024	Fidelis Capital Partners LLC	762	$53K	0.0%	N/A	0.001%
5/1/2024	BNP Paribas Financial Markets	65,608	$4.54M	0.0%	-75.2%	0.068%
5/1/2024	Mirae Asset Global Investments Co. Ltd.	43,754	$3.03M	0.0%	-4.1%	0.045%
4/30/2024	Privium Fund Management B.V.	108,883	$7.54M	2.0%	+15.9%	0.112%
4/29/2024	Principal Financial Group Inc.	527,368	$36.49M	0.0%	+14.5%	0.545%
4/29/2024	China Universal Asset Management Co. Ltd.	18,613	$1.29M	0.2%	+67.2%	0.018%
4/26/2024	Pinnacle Associates Ltd.	173,892	$12.03M	0.2%	-1.3%	0.180%
4/24/2024	Gemmer Asset Management LLC	4,000	$0.28M	0.0%	-33.3%	0.004%
4/24/2024	Assenagon Asset Management S.A.	649,817	$44.97M	0.1%	-14.9%	0.671%
4/23/2024	Global Retirement Partners LLC	765	$53K	0.0%	-39.3%	0.001%
4/22/2024	PFG Investments LLC	13,800	$0.96M	0.1%	+392.9%	0.014%
4/22/2024	Raymond James & Associates	156,046	$10.80M	0.0%	+12.4%	0.161%
4/19/2024	Handelsinvest Investeringsforvaltning	3,217	$0.22M	0.1%	-34.2%	0.003%
4/18/2024	Wasatch Advisors LP	3,854,747	$266.75M	1.4%	+6.3%	3.982%
4/18/2024	Allspring Global Investments Holdings LLC	16,374	$1.13M	0.0%	-28.9%	0.017%
4/17/2024	Hennion & Walsh Asset Management Inc.	16,651	$1.15M	0.1%	+14.4%	0.017%
4/5/2024	First Hawaiian Bank	5,973	$0.41M	0.0%	-2.8%	0.006%
4/5/2024	Los Angeles Capital Management LLC	16,024	$1.11M	0.0%	-8.8%	0.017%
3/29/2024	Kapitalo Investimentos Ltda	368	$26K	0.0%	N/A	0.000%
3/26/2024	HighPoint Advisor Group LLC	3,199	$0.22M	0.0%	N/A	0.003%
3/22/2024	PNC Financial Services Group Inc.	3,795	$0.27M	0.0%	-5.9%	0.004%
3/11/2024	Vanguard Group Inc.	9,094,302	$651.33M	0.0%	+6.5%	9.394%
3/5/2024	Wellington Management Group LLP	1,763,475	$126.30M	0.0%	-2.9%	1.822%
3/1/2024	Goldman Sachs Group Inc.	578,615	$41.44M	0.0%	+52.6%	0.598%
2/28/2024	American International Group Inc.	46,576	$3.34M	0.0%	-0.4%	0.048%
2/26/2024	Virtu Financial LLC	7,623	$0.55M	0.0%	N/A	0.008%
2/26/2024	Perceptive Advisors LLC	108,000	$7.74M	0.2%	N/A	0.112%
2/20/2024	Quarry LP	1,000	$72K	0.0%	-69.7%	0.001%
2/15/2024	Parkman Healthcare Partners LLC	186,272	$13.34M	1.9%	N/A	0.194%
2/15/2024	Great Point Partners LLC	110,607	$7.92M	1.4%	-50.8%	0.115%
2/14/2024	Avidity Partners Management LP	710,000	$50.85M	1.9%	-11.4%	0.738%
2/14/2024	Wasatch Advisors LP	3,627,308	$259.79M	1.4%	-4.6%	3.769%

Data available starting January 2016

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Today's Range

Now: $80.39

$79.43

$82.00

50 Day Range

MA: $71.53

$65.32

$80.84

52 Week Range

Now: $80.39

$45.50

$84.89

Volume

625,486 shs

Average Volume

1,018,489 shs

Market Capitalization

$8.49 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.01

Who are the company insiders with the largest holdings of Intra-Cellular Therapies?: Intra-Cellular Therapies' top insider shareholders include:
Sharon Mates (CEO)
Rory B Riggs (Director)
Mark Neumann (EVP)
Joel S Marcus (Director)
Lawrence J Hineline (CFO)
Michael Halstead (EVP)
Suresh K Durgam (EVP)
Suresh K Durgam (SVP)
Nostrand Robert L Van (Director)
Suresh K Durgam (EVP)
Learn More about top insider investors at Intra-Cellular Therapies.
Who are the major institutional investors of Intra-Cellular Therapies?: Intra-Cellular Therapies' top institutional shareholders include:
Bank of New York Mellon Corp — 0.33%
Assenagon Asset Management S.A. — 0.32%
Raymond James & Associates — 0.15%
DNB Asset Management AS — 0.08%
Allspring Global Investments Holdings LLC — 0.07%
SG Americas Securities LLC — 0.05%
Learn More about top institutional investors of Intra-Cellular Therapies stock.
Which institutional investors are selling Intra-Cellular Therapies stock?: In the previous quarter, ITCI stock was sold by these institutional investors:
Assenagon Asset Management S.A.
Bank of New York Mellon Corp
OLD National Bancorp IN
China Universal Asset Management Co. Ltd.
Franklin Street Advisors Inc. NC
Raymond James & Associates
Envestnet Portfolio Solutions Inc.
Raymond James Trust N.A.
During the last year, company insiders that have sold Intra-Cellular Therapies company stock include:
Sharon Mates (CEO)
Rory B Riggs (Director)
Mark Neumann (EVP)
Joel S Marcus (Director)
Lawrence J Hineline (CFO)
Michael Halstead (EVP)
Suresh K Durgam (EVP)
Suresh K Durgam (SVP)
Nostrand Robert L Van (Director)
Learn More investors selling Intra-Cellular Therapies stock.
Which institutional investors are buying Intra-Cellular Therapies stock?: During the last quarter, ITCI stock was acquired by institutional investors including:
Allspring Global Investments Holdings LLC
SG Americas Securities LLC
Harbor Capital Advisors Inc.
DNB Asset Management AS
Oak Ridge Investments LLC
Legato Capital Management LLC
Calamos Advisors LLC
AlphaMark Advisors LLC